IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 8,361 shares of the medical research company’s stock after purchasing an additional 900 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in IQVIA were worth $1,643,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter worth approximately $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA during the 3rd quarter valued at $28,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC acquired a new stake in IQVIA in the 4th quarter valued at $33,000. Finally, Assetmark Inc. raised its position in IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $200.00 on Wednesday. The company has a market cap of $36.30 billion, a PE ratio of 26.25, a P/E/G ratio of 2.15 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a fifty day moving average price of $200.31 and a two-hundred day moving average price of $220.14. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent research reports. The Goldman Sachs Group lowered their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Truist Financial dropped their price objective on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Morgan Stanley dropped their price target on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Five investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $254.53.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.